Urovant Sciences (UROV) News Today → How to camouflage a factory of 53,000 workers (From Stansberry Research) (Ad) Free UROV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineA2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directorsfinance.yahoo.com - March 26 at 3:06 AMPetauri™ Elects William Fleming and James Robinson to Its Board of Directorsfinance.yahoo.com - December 6 at 10:09 AMPM360 Announces 2023 Trailblazer Award Winnersfinance.yahoo.com - October 4 at 8:59 AMEledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directorsfinance.yahoo.com - September 11 at 8:30 AMCNVCF - BioHarvest Sciences Inc.finance.yahoo.com - July 31 at 2:30 AMUroGen Pharma Announces the Appointment of James Robinson to its Board of Directorsbusinesswire.com - July 25 at 5:44 PMBenign Prostatic Hyperplasia Therapeutics Market Size Predictions suggest a rise of 5.1% CAGR, to reach value of USD 12.9 Billion by 2032benzinga.com - July 20 at 2:12 PMKPCW Cool Science Radionpr.org - June 24 at 2:07 PMOveractive Bladder Treatment Global Market Report 2023uk.finance.yahoo.com - June 9 at 2:30 PMPierre Fabre announces start of EU marketing authorization application procedure for Vibegron in overactive bladderfinanznachrichten.de - May 22 at 12:33 PMThree Japanese pharma subsidiaries to lay off 223 in Marlboroughbizjournals.com - May 3 at 1:52 PMOveractive Bladder Market to Grow Rapidly at a Considerable CAGR During the Forecast Period (2023–2032) | DelveInsightfinance.yahoo.com - March 28 at 4:12 PMDrugs for Enuresis Market 2023: Growth by 2029 Top Players with Opportunitiesmarketwatch.com - February 19 at 1:43 PMUrovant Sciences® Announces Collaboration with Holly Robinson Peete to Help Raise Awareness for Overactive Bladder and Treatment Optionstechnews.tmcnet.com - January 19 at 8:35 AMDrugs for Enuresis Market Share From 2023 To 2029 And Unlimited Opportunities for New Companies and Latest Developmentsmarketwatch.com - January 16 at 10:02 AMHow To Deal With An Overactive Bladder If You're Traveling Long Distance Over The Holidaysmsn.com - December 21 at 2:41 PMRoivant Sciences: A Solid Year Of Progress And Good Prospects For 2023seekingalpha.com - December 20 at 6:02 PMUrovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tabletfinance.yahoo.com - October 27 at 3:52 PMMyovant: Sumitomo Bid Is A Head Scratcher, Where Is The Value?seekingalpha.com - October 4 at 3:38 PM'I lose money every time I leave the house': Inflation complicates back-to-office pushfinancialpost.com - September 30 at 1:31 PMSocial Science: What It Is and the 5 Major Branchesinvestopedia.com - September 26 at 5:34 PMBest Global Universities for Computer Scienceusnews.com - September 13 at 3:11 AMScience Fridaynpr.org - September 10 at 7:14 PMHealth and Sciencecnbc.com - September 8 at 7:09 AMUrovant Sciences, Inc.: Urovant Sciences Named 17th on the List of Fortune Best Workplaces in BioPharma (2022)finanznachrichten.de - September 7 at 10:52 AMUrovant Sciences® Named 17th on the List of Fortune® Best Workplaces in BioPharma™ (2022)finance.yahoo.com - September 7 at 10:52 AMThe Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities in the U.S. Highlighted in New Surveyfinance.yahoo.com - July 13 at 3:25 PMUrovant Sciences, Inc.: Urovant Sciences Named One of 2022 "Best Places to Work" in Orange Countyfinanznachrichten.de - July 9 at 6:45 AMPierre Fabre to commercialize Urovant's overactive bladder treatment vibegron in Europeseekingalpha.com - July 7 at 7:53 AMOveractive Bladder Treatment (OAB) Market worth $4.2 Billion by 2027 - Exclusive Report by MarketsandMarketsfinanznachrichten.de - July 5 at 3:25 PMUrovant Sciences, Inc.: Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical Officerfinanznachrichten.de - April 4 at 3:34 PMUrovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical Officerfinance.yahoo.com - April 4 at 3:34 PMCORRECTING and REPLACING Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical Officerapnews.com - April 4 at 3:34 PMUrovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902finance.yahoo.com - March 7 at 1:01 PMMyovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updatesstockhouse.com - October 26 at 9:13 AMUrovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansionfinance.yahoo.com - October 18 at 12:40 PMUrovant Sciences Appoints Betzy Estrada as Executive Vice President and Chief Human Resources Officerfinance.yahoo.com - August 12 at 4:44 PMUrovant Sciences Ltd. Common Shares (UROV)nasdaq.com - July 25 at 12:20 AM Get Urovant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for UROV and its competitors with MarketBeat's FREE daily newsletter. Email Address How to camouflage a factory of 53,000 workers (Ad)"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio." Get the full story here. UROV Media Mentions By Week UROV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UROV News Sentiment▼0.000.43▲Average Medical News Sentiment UROV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UROV Articles This Week▼00▲UROV Articles Average Week Get Urovant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for UROV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PHAT News ATXS News AVBP News ALT News STOK News KRRO News CALT News ANAB News PAHC News CMPS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UROV) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold GroupWill this $2 AI stock double overnight?Behind the MarketsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urovant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
